DECIDE Program Benefits for African-Americans With Type 2 Diabetes
For African-Americans with type 2 diabetes, the DECIDE program is beneficial.
HealthDay News -- For African-Americans with type 2 diabetes, the Decision-making Education for Choices In Diabetes Everyday (DECIDE) program is beneficial, according to a study published in Diabetes Care.
Stephanie L. Fitzpatrick, PhD, from the Johns Hopkins University School of Medicine in Baltimore, and colleagues compared the effectiveness of DECIDE with Enhanced Usual Care among 182 urban African-Americans with type 2 diabetes with a suboptimal cardiovascular disease risk factor profile. Participants were randomly allocated to DECIDE Self-Study (46 participants), DECIDE Individual (45 participants), DECIDE Group (46 participants), or Enhanced Usual Care (45 participants) for 18 to 20 weeks.
The researchers observed no significant difference in clinical outcomes for DECIDE modalities and Enhanced Usual Care at 6 months after the intervention. For participants with HbA1c ≥7.5% at baseline, there was a decrease with each DECIDE modality at 1 week post-intervention (P <.05), and a decrease at 6 months after the intervention in Self-Study only (P <.05).
In Self-Study and Enhanced Usual Care Group, there was a significant reduction in systolic blood pressure at 6 months after the intervention. Significant decreases were seen in LDL cholesterol in Self-Study, Individual, and Enhanced Usual Care; Self-Study had an increase in HDL cholesterol at 6 months after the intervention.
"DECIDE modalities showed benefits after intervention," the researchers wrote. "Self-Study demonstrated robust improvements across clinical and behavioral outcomes, suggesting program suitability for broader dissemination to populations with similar educational and literacy levels."
- Fitzpatrick SL, Golden SH, Stewart K, et al. Effect of DECIDE (Decision-making Education for Choices In Diabetes Everyday) program delivery modalities on clinical and behavioral outcomes in urban African Americans with type 2 diabetes: a randomized trial. Diabetes Care. 2016;39(12):2149-2157. doi:10.2337/dc16-0941.